Altimmune says ‘double G’ drug has even better lean mass preservation data in obesity trial update

ORLANDO – Altimmune is back with a full Phase 2 analysis of its “double G” drug pemvidutide, with the company touting it is much better …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Al­tim­mune says ‘dou­ble G’ drug has even bet­ter lean mass preser­va­tion da­ta in obe­si­ty tri­al up­date